StoneX Group’s ProShares Ultra CRCL CRCA Stock Holding History

StoneX Group’s Portfolio CRCA Stock Details CRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-6,511	Closed	-$288K	–	2296
2026 Q2	$288K	Buy	+6,511	New	+$251K	0.01%	850
2026 Q1	–	Sell	-6,027	Closed	-$243K	–	1303
2025 Q4	$243K	Buy	+6,027	New	+$517K	0.01%	791

StoneX Group's CRCA Position: Q3 2026 in Review

StoneX Group sold out of ProShares Ultra CRCL (CRCA) in Q3 2026, closing a stake of 6,511 shares — an estimated $288K sold.

StoneX Group first reported a position in CRCA in Q4 2025 and held it in 2 quarters. The position peaked at $288K in Q2 2026. 0 funds tracked by Wall St. Rank hold CRCA as of Q3 2026.

StoneX Group reported no remaining ProShares Ultra CRCL position as of Q3 2026 after selling out during the quarter.
StoneX Group sold 6,511 ProShares Ultra CRCL shares in Q3 2026, an estimated $288K.
StoneX Group first reported a position in ProShares Ultra CRCL in Q4 2025 and held it in 2 quarters.
StoneX Group's ProShares Ultra CRCL position peaked at $288K in Q2 2026.
0 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.